Clinical Trial ProgressLAE102’s phase 1 clinical trial is set to complete soon; more data could trigger licensing interest from Eli Lilly and other global players.
Licensing OpportunityThere is a higher likelihood that Eli Lilly will license in Laekna’s LAE102 for muscle loss prevention, with Eli Lilly’s clinical trial disclosures suggesting LAE102 may be a stronger candidate for the indication.
Market ValuationThe valuation of obesity drug acquisitions suggests significant upside for Laekna, given its market cap and its potential to address the key weakness of obesity drugs.